PYXS Pyxis Oncology Inc revenue, earnings and financials
For the quarter ended June 30, 2026, Pyxis Oncology Inc reported revenue of n/a, net income of −$25.3M and diluted EPS of −$0.40; for the fiscal year ended December 2025 revenue was $13.9M, down 14.2% on the year before.
PYXS annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $13.9M, gross profit n/a, operating income −$84.4M, net income −$79.6M (margin -574.5%), EPS −$1.28
- Fiscal year ended Dec 2024: revenue $16.1M, gross profit n/a, operating income −$89.5M, net income −$77.3M (margin -478.9%), EPS −$1.32
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$82.2M, net income −$73.8M (margin n/a), EPS −$1.85
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$123M, net income −$121M (margin n/a), EPS −$3.65
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$69.7M, net income −$76.0M (margin n/a), EPS −$8.95
PYXS quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$25.3M, EPS −$0.40
- Quarter ended Mar 31, 2026: revenue n/a, net income −$23.3M, EPS −$0.37
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$18.1M, EPS −$0.28
- Quarter ended Sep 30, 2025: revenue n/a, net income −$22.0M, EPS −$0.35
- Quarter ended Jun 30, 2025: revenue $2.82M, net income −$18.4M, EPS −$0.30
- Quarter ended Mar 31, 2025: revenue n/a, net income −$21.2M, EPS −$0.35
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$35.6M, EPS −$0.62
- Quarter ended Sep 30, 2024: revenue n/a, net income −$21.2M, EPS −$0.35
- Quarter ended Jun 30, 2024: revenue n/a, net income −$17.3M, EPS −$0.29
- Quarter ended Mar 31, 2024: revenue $16.1M, net income −$3.26M, EPS −$0.06
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$15.6M, EPS −$0.34
- Quarter ended Sep 30, 2023: revenue n/a, net income −$23.0M, EPS −$0.56
- Quarter ended Jun 30, 2023: revenue n/a, net income −$15.9M, EPS −$0.41
- Quarter ended Mar 31, 2023: revenue n/a, net income −$19.2M, EPS −$0.54
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$36.1M, EPS −$1.04
- Quarter ended Sep 30, 2022: revenue n/a, net income −$27.7M, EPS −$0.85
- Quarter ended Jun 30, 2022: revenue n/a, net income −$25.6M, EPS −$0.79
- Quarter ended Mar 31, 2022: revenue n/a, net income −$31.4M, EPS −$0.97
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$16.8M, EPS $32.81
- Quarter ended Sep 30, 2021: revenue n/a, net income −$14.2M, EPS −$8.96
PYXS cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$63.5M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$57.7M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$70.7M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$89.3M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$35.3M, share buybacks n/a
PYXS balance sheet
- Jun 30, 2026: cash $18.9M, total assets $54.9M, total liabilities $43.5M, shareholders' equity $11.4M
- Mar 31, 2026: cash $5.77M, total assets $64.3M, total liabilities $33.0M, shareholders' equity $31.3M
- Dec 31, 2025: cash $15.4M, total assets $91.5M, total liabilities $38.1M, shareholders' equity $53.4M
- Sep 30, 2025: cash $8.92M, total assets $106M, total liabilities $36.8M, shareholders' equity $68.8M
- Jun 30, 2025: cash $10.7M, total assets $123M, total liabilities $35.6M, shareholders' equity $87.6M
- Mar 31, 2025: cash $12.8M, total assets $136M, total liabilities $32.8M, shareholders' equity $103M
- Dec 31, 2024: cash $19.5M, total assets $157M, total liabilities $36.4M, shareholders' equity $121M
- Sep 30, 2024: cash $12.1M, total assets $195M, total liabilities $41.6M, shareholders' equity $154M
What is PYXS's revenue?
Pyxis Oncology Inc reported $13.9M of revenue for the fiscal year ended December 2025.
Is PYXS profitable?
No. Pyxis Oncology Inc lost $88.7M over the last four quarters.
What is PYXS's EPS?
Diluted earnings per share over the last four quarters were −$1.40; −$0.40 in the latest quarter.